Clinical trial NCT00391287: Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure
Official title: A Prospective, Immunogenicity Surveillance Registry (PRIMS) to Estimate the Incidence of Erythropoietin Antibody-Mediated Pure Red Cell Aplasia Among Subjects With Chronic Renal Failure and Subcutaneous Exposure to Recombinant Erythropoietin Products
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pure Red-Cell Aplasia
Chronic Kidney Failure
Keywords: Red-Cell Aplasia due to Chronic Kidney Failure
Aplastic Anemia
Recombinant Erythropoietin
Surveillance Registry
Registries
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor class: INDUSTRY
Collaborators: name: Janssen-Cilag International NV
First posted: 2006-10-23
Enrollment: 15334
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients should have documented chronic renal failure (CRF) and be receiving or about to receive (within 1 month) a marketed erythropoietin product by the subcutaneous route of administration at the time of enrollment. Patients may be at any stage of CRF (Stages 1 to 5) or be receiving any treatment for CRF, including predialysis, peritoneal dialysis, or hemodialysis, but should not be receiving immunosuppressive treatment following an organ transplant.

Patients will be enrolled at sites located in the E.U. and Australia.

Brief summary: The purpose of this study is to estimate the incidence rate of pure red cell aplasia (PRCA; aplastic anemia) mediated by erythropoietin (EPO) antibodies in patients who are receiving subcutaneous (s.c.) epoetin alfa (polysorbate 80 formulation) for the treatment of anemia associated with chronic renal failure (CRF), and to compare this incidence rate to the incidence rate with s.c. exposure to other currently marketed recombinant erythropoietin products (epoetin alfa, epoetin beta, darbepoetin alfa), with adjustment of duration for which the drug is given to the patient. The study will also examine the impact of the pattern of using mixed s.c. exposure to multiple erythropoietin products occurring in this patients, and the impact of the time from which the treatment is started to the onset of PRCA.

Detailed description: In 1998, prompted by concern that human serum albumin (HAS- the stabilizer in the epoetin alfa formulation) could theoretically transmit Creutzfeldt-Jakob disease and bovine spongiform encephalopathy, an alternative epoetin alfa formulation using polysorbate 80 as a stabilizer was introduced. The polysorbate 80 epoetin alfa formulation became available in a variety of product presentations (i.e., single-use vials and prefilled syringes with both coated and uncoated stoppers) to provide for prescribing flexibility, patient convenience, and choice of route of administration. Soon after the introduction of the polysorbate 80 epoetin alfa formulation in prefilled syringes, an increasing number of cases of EPO antibody-mediated pure red cell aplasia (PRCA) were reported in patients with chronic renal failure (CRF) exposed to epoetin alfa by the s.c. route. This led to contraindication of the s.c. route for epoetin alfa in the European Union (E.U.) and Switzerland in December 2002. It was subsequently shown that the increased risk for PRCA was associated with one specific polysorbate 80 epoetin alfa presentation - prefilled syringes with uncoated rubber stoppers. It appeared that uncoated rubber stoppers, when exposed to polysorbate 80, released organic compounds (leachates) into the epoetin alfa formulation, and that these leachates were the most probable product-specific cause for the increase in EPO antibody-mediated PRCA. A worldwide recall of the polysorbate 80 epoetin formulation in prefilled syringes with uncoated stoppers was completed in March 2004. FluroTec-coated stoppers are now used in all prefilled syringes containing the polysorbate 80 epoetin alfa formulation, to prevent leachates from entering the formulation. Following these actions, the incidence rate of EPO antibody-mediated PRCA in CRF patients receiving s.c. epoetin alfa fell to a level similar to that for the HSA-containing epoetin formulation, which has a long-standing and well-characterized safety profile. As of 30 November 2005, s.c. exposure in CRF patients to the polysorbate 80 epoetin alfa formulation in prefilled syringes with coated stoppers was 71,880 patient-years, with 4 cases of EPO antibody-mediated PRCA reported. In 2006, E.U. Health Authorities reauthorized s.c. epoetin alfa use in CRF patients for whom intravenous access is not readily available. As part of the reauthorization, the sponsor agreed to conduct this registry in order to demonstrate that the polysorbate 80 epoetin alfa formulation using a coated stopper has an acceptable immunogenic safety profile and to define the incidence of EPO antibody-mediated PRCA associated with recombinant erythropoietin use among patients with anemia associated with CRF. This is a multicenter, multinational, immunogenicity surveillance registry using a prospective cohort design (patients identified by a common characteristic), with enrollment of parallel groups that are exposed to the polysorbate 80 formulation of epeotin alfa or other marketed erythropoietin products administered by the s.c. route of administration for the treatment of anemia associated with CRF. The registry is designed to address the following question: Is the current rate of PRCA with the s.c. polysorbate 80 epoetin alfa formulation using coated stoppers similar to the current rate with other marketed erythropoietin products administered by the s.c. route, adjusted for duration of exposure? Each patient will be observed for development of PRCA for up to 3 years. Information on exposure to erythropoietin products, stage of CRF, treatment modality for CRF, erythropoietin handling and storage information, and most recent hemoglobin level will be collected quarterly. Cases of unexplained loss or lack of effect (LOE) with an administered erythropoietin product, including cases of suspected PRCA, will be reported to the sponsor as serious adverse events. Cases of EPO antibody-mediated PRCA will be determined by the clinical presence of suspected PRCA, an unexplained LOE with administered erythropoietin product, and the presence of EPO antibody. An Independent Case Adjudication Committee will review blinded case data for patients with unexplained LOE and identify cases of EPO antibody-mediated PRCA. A separate Independent Safety Advisory Committee will be responsible for periodically reviewing unblinded patient data and summary data and will make recommendations related to the incidence rate of PRCA associated with s.c. epoetin alfa use. The sponsor will actively monitor registry enrollment and erythropoietin brand usage to ensure that the registry accrues 20,000 person-years of s.c. exposure to epoetin alfa and 20,000 person-years of s.c. exposure to all other erythropoietin products combined. If it appears that one registry arm will meet this accrual goal before the other, the sponsor may elect to selectively close those investigational sites with predominant use of the erythropoietin product(s) in the arm approaching full accrual. The registry will provide no inducement to change therapy and will be non-interventional.

Eligibility criteria: Inclusion Criteria:

* Patients with established CRF as an indication for the treatment of anemia
* Patients who are receiving or are about to receive (within 1 month) a marketed erythropoietin (i.e., epoetin alfa \[EPREX/ERYPO/GLOBUREN\], epoetin beta \[NEORECORMON®\], or darbepoetin alfa \[ARANESP®\]) by the s.c. route of administration
* Patients who are likely to continue to receive s.c. erythropoietin product(s) for at least 1 year.

Exclusion Criteria:

* Patients with a history of pure red cell aplasia or aplastic anemia
* Patients who are experiencing unexplained loss or lack of effect to a recombinant erythropoietin product ongoing at the time of enrollment
* Patients who have had prior recombinant erythropoietin treatment whose anemia had never responded (primary lack of efficacy)
* Patients with a history of EPO antibodies prior to enrollment
* Subjects who are currently receiving immunosuppressive medication (e.g., cyclosporine, tacrolimus, sirolimus, mycophenolic mofetil, azathioprine, or monoclonal antibodies) or corticosteroids at a dose corresponding to \>15 mg/day prednisolone
* Subjects whose first s.c. exposure to any erythropoietin product was \>1 year prior to enrollment.

Primary outcomes:
measure: estimate the incidence rate of EPO antibody-mediated Pure Red Cell Aplasia (PRCA)
timeFrame: Unexplained Loss of Effect (LOE) follow-up
Secondary outcomes:
measure: sensitivity analyses
timeFrame: Unexplained Loss of Effect (LOE) follow-up
Other outcomes:
Locations:
city: Adelaide
country: Australia
city: Central Queensland M C
country: Australia
city: Fremantle
country: Australia
city: Hobart
country: Australia
city: Launceston
country: Australia
city: Liverpool
country: Australia
city: Newcastle
country: Australia
city: Parkville
country: Australia
city: Perth
country: Australia
city: Randwick
country: Australia
city: Wollongong
country: Australia
city: Woodville
country: Australia
city: Aalst
country: Belgium
city: Antwerpen
country: Belgium
city: Arlon
country: Belgium
city: Assebroek
country: Belgium
city: Ath
country: Belgium
city: Bonheiden
country: Belgium
city: Brugge
country: Belgium
city: Brussels
country: Belgium
city: Brussel
country: Belgium
city: Charleroi
country: Belgium
city: Deinze
country: Belgium
city: Doornik
country: Belgium
city: Edegem
country: Belgium
city: Eeklo
country: Belgium
city: Frameries
country: Belgium
city: Genk
country: Belgium
city: Gent
country: Belgium
city: Gilly
country: Belgium
city: Huy
country: Belgium
city: Ieper
country: Belgium
city: La Louviere
country: Belgium
city: Leuven
country: Belgium
city: Liege
country: Belgium
city: Liège
country: Belgium
city: Mons
country: Belgium
city: Namur
country: Belgium
city: Roeselare
country: Belgium
city: Sint-Gillis-Dendermonde
country: Belgium
city: Sint-Niklaas
country: Belgium
city: St-Truiden
country: Belgium
city: Turnhout
country: Belgium
city: Westmalle
country: Belgium
city: Wilrijk
country: Belgium
city: Holstebro N/A
country: Denmark
city: Sønderborg
country: Denmark
city: Viborg
country: Denmark
city: Århus N N/A
country: Denmark
city: Helsinki
country: Finland
city: Tampere
country: Finland
city: Turku
country: Finland
city: Aachen
country: Germany
city: Aalen
country: Germany
city: Altötting
country: Germany
city: Alzey
country: Germany
city: Annaberg-Buchholz
country: Germany
city: Ansbach
country: Germany
city: Arnstadt
country: Germany
city: Aschersleben
country: Germany
city: Augsburg
country: Germany
city: Aurich
country: Germany
city: Bad Bevensen
country: Germany
city: Bad Ems
country: Germany
city: Bad Homburg
country: Germany
city: Bad Krozingen
country: Germany
city: Bad König
country: Germany
city: Bad Mergentheim
country: Germany
city: Bad Nenndorf
country: Germany
city: Bad Oeynhausen
country: Germany
city: Bad Tölz
country: Germany
city: Bassum
country: Germany
city: Bergisch Gladbach
country: Germany
city: Berlin
country: Germany
city: Bernburg
country: Germany
city: Betzdorf
country: Germany
city: Biberach
country: Germany
city: Bielefeld
country: Germany
city: Bischofswerda
country: Germany
city: Bonn
country: Germany
city: Braunschweig
country: Germany
city: Bremen
country: Germany
city: Bremerhaven
country: Germany
city: Coburg
country: Germany
city: Cochem
country: Germany
city: Coesfeld
country: Germany
city: Cottbus
country: Germany
city: Darmstadt
country: Germany
city: Deggendorf
country: Germany
city: Dillingen
country: Germany
city: Dinkelsbühl
country: Germany
city: Dormagen
country: Germany
city: Düsseldorf
country: Germany
city: Eberswalde
country: Germany
city: Eisenach
country: Germany
city: Elmshorn
country: Germany
city: Elsenfeld
country: Germany
city: Emmering
country: Germany
city: Emsdetten
country: Germany
city: Erftstadt
country: Germany
city: Erfurt
country: Germany
city: Erkelenz
country: Germany
city: Essen
country: Germany
city: Finsterwalde
country: Germany
city: Flensburg
country: Germany
city: Frankfurt
country: Germany
city: Freiberg
country: Germany
city: Freiburg
country: Germany
city: Fürstenwalde
country: Germany
city: Fürstenzell
country: Germany
city: Fürth
country: Germany
city: Gera
country: Germany
city: Greifswald
country: Germany
city: Göppingen
country: Germany
city: Gütersloh
country: Germany
city: Hagenow
country: Germany
city: Halberstadt
country: Germany
city: Hamburg
country: Germany
city: Hameln
country: Germany
city: Hannover
country: Germany
city: Haßfurt
country: Germany
city: Heidenau
country: Germany
city: Heilbronn
country: Germany
city: Helmstedt
country: Germany
city: Herford
country: Germany
city: Herzberg
country: Germany
city: Hilden
country: Germany
city: Hildesheim
country: Germany
city: Hoyerswerda
country: Germany
city: Hürth
country: Germany
city: Ibbenbüren
country: Germany
city: Immenstadt
country: Germany
city: Ingolstadt
country: Germany
city: Jena
country: Germany
city: Kaiserslautern
country: Germany
city: Kamen
country: Germany
city: Kelheim
country: Germany
city: Kempten
country: Germany
city: Kerpen
country: Germany
city: Kiel
country: Germany
city: Kleve
country: Germany
city: Kronach
country: Germany
city: Kulmbach
country: Germany
city: Köln
country: Germany
city: Lahr
country: Germany
city: Landshut
country: Germany
city: Landstuhl
country: Germany
city: Langenfeld
country: Germany
city: Langenhagen
country: Germany
city: Langenselbold
country: Germany
city: Lehrte
country: Germany
city: Leipzig
country: Germany
city: Leverkusen
country: Germany
city: Lichtenfels
country: Germany
city: Lindau
country: Germany
city: Linnich
country: Germany
city: Lohr
country: Germany
city: Lutherstadt Wittenberg
country: Germany
city: Lübeck
country: Germany
city: Lüdenscheid
country: Germany
city: Lüneburg
country: Germany
city: Magdeburg
country: Germany
city: Malente
country: Germany
city: Mannheim
country: Germany
city: Marburg
country: Germany
city: Markkleeberg
country: Germany
city: Marl
country: Germany
city: Mayen
country: Germany
city: Meiningen
country: Germany
city: Moers
country: Germany
city: Mönchengladbach
country: Germany
city: Mühlhausen
country: Germany
city: München
country: Germany
city: Münster
country: Germany
city: Neubrandenburg
country: Germany
city: Neunkirchen
country: Germany
city: Neuruppin
country: Germany
city: Nürnberg
country: Germany
city: Nürtingen
country: Germany
city: Oberschleißheim
country: Germany
city: Offenburg
country: Germany
city: Olpe
country: Germany
city: Passau
country: Germany
city: Peine
country: Germany
city: Pfaffenhofen
country: Germany
city: Pforzheim
country: Germany
city: Potsdam
country: Germany
city: Quedlinburg
country: Germany
city: Regensburg
country: Germany
city: Remagen
country: Germany
city: Rosenheim
country: Germany
city: Rostock
country: Germany
city: Rüsselsheim
country: Germany
city: Saarlouis
country: Germany
city: Sachsen
country: Germany
city: Salzgitter
country: Germany
city: Schwabach
country: Germany
city: Schwedt
country: Germany
city: Schweinfurt
country: Germany
city: Schwerin
country: Germany
city: Schönebeck
country: Germany
city: Seehausen
country: Germany
city: Seelow
country: Germany
city: Siegen
country: Germany
city: Sigmaringen
country: Germany
city: Sindelfingen
country: Germany
city: Singen
country: Germany
city: Sinsheim
country: Germany
city: Sonneberg
country: Germany
city: Spremberg
country: Germany
city: St Martin
country: Germany
city: St Wendel
country: Germany
city: Stade
country: Germany
city: Straubing
country: Germany
city: Stuttgart
country: Germany
city: Suhl
country: Germany
city: Tangermünde
country: Germany
city: Traunstein
country: Germany
city: Uelzen
country: Germany
city: Viersen
country: Germany
city: Villingen-Schwenningen
country: Germany
city: Waiblingen
country: Germany
city: Waldshut-Tiengen
country: Germany
city: Weinheim
country: Germany
city: Weißenburg
country: Germany
city: Weißenfels
country: Germany
city: Weißwasser
country: Germany
city: Wesseling
country: Germany
city: Weyhausen
country: Germany
city: Wiesbaden
country: Germany
city: Wolfenbüttel
country: Germany
city: Worms
country: Germany
city: Wuppertal
country: Germany
city: Würzburg
country: Germany
city: Zirndorf
country: Germany
city: Zwickau
country: Germany
city: Alexandroupolis
country: Greece
city: Athens
country: Greece
city: Chalkida
country: Greece
city: Didimoteicho
country: Greece
city: Edessa
country: Greece
city: Grevena
country: Greece
city: Ioannina
country: Greece
city: Iraklio
country: Greece
city: Larisa
country: Greece
city: Piraias
country: Greece
city: Rodos
country: Greece
city: Serres
country: Greece
city: Thessalonikis
country: Greece
city: Thessaloniki
country: Greece
city: Veroia
country: Greece
city: Cork
country: Ireland
city: Galway
country: Ireland
city: 'S-Hertogenbosch
country: Netherlands
city: Apeldoorn
country: Netherlands
city: Rotterdam
country: Netherlands
city: Weert
country: Netherlands
city: Oslo
country: Norway
city: Trondheim N/A
country: Norway
city: Tvnsberg
country: Norway
city: Bialystok
country: Poland
city: Bytom
country: Poland
city: Chojnice
country: Poland
city: Ciechanow
country: Poland
city: Dzialdowo
country: Poland
city: Gdansk-Zaspa
country: Poland
city: Gdansk
country: Poland
city: Koszalin
country: Poland
city: Lodz
country: Poland
city: Lomza N/A
country: Poland
city: Lublin
country: Poland
city: Olawa
country: Poland
city: Poznan
country: Poland
city: Proszowice
country: Poland
city: Radomsko
country: Poland
city: Rybnik
country: Poland
city: Stalowa Wola N/A
country: Poland
city: Torun
country: Poland
city: Warszawa
country: Poland
city: Wroclaw
country: Poland
city: Aveiro
country: Portugal
city: Barcelos
country: Portugal
city: Braga
country: Portugal
city: Coimbra
country: Portugal
city: Evora N/A
country: Portugal
city: Faro
country: Portugal
city: Leiria
country: Portugal
city: P-1100 Lisboa N/A
country: Portugal
city: Portalegre
country: Portugal
city: Porto
country: Portugal
city: S. Joao Da Madeira
country: Portugal
city: Setubal N/A
country: Portugal
city: Viana Do Castelo
country: Portugal
city: Vila Nova De Gaia
country: Portugal
city: Alcorcon
country: Spain
city: Barcelona
country: Spain
city: Burgos
country: Spain
city: Castellón
country: Spain
city: Girona
country: Spain
city: Leganés
country: Spain
city: León
country: Spain
city: Madrid
country: Spain
city: Manresa
country: Spain
city: Maranon
country: Spain
city: Mollet Del Valles
country: Spain
city: Oviedo
country: Spain
city: Palma De Mallorca
country: Spain
city: Sabadell
country: Spain
city: Santa Cruz De Tenerife
country: Spain
city: Santander
country: Spain
city: Teruel
country: Spain
city: Valencia N/A
country: Spain
city: Valencia
country: Spain
city: Valladolid
country: Spain
city: Zaragoza
country: Spain
city: Avesta
country: Sweden
city: Bollnäs
country: Sweden
city: Borås
country: Sweden
city: Eksjö
country: Sweden
city: Eskilstuna
country: Sweden
city: Gällivare
country: Sweden
city: Gävle
country: Sweden
city: Göteborg
country: Sweden
city: Halmstad
country: Sweden
city: Karlshamn
country: Sweden
city: Karlskoga
country: Sweden
city: Karlskrona
country: Sweden
city: Köping
country: Sweden
city: Linköping
country: Sweden
city: Lulea
country: Sweden
city: Malmö
country: Sweden
city: Norrköping
country: Sweden
city: Nyköping
country: Sweden
city: Skellefteå
country: Sweden
city: Skene
country: Sweden
city: Skövde
country: Sweden
city: Stockholm N/A
country: Sweden
city: Stockholm
country: Sweden
city: Sundsvall
country: Sweden
city: Trollhättan
country: Sweden
city: Umeå
country: Sweden
city: Uppsala
country: Sweden
city: Varberg N/A
country: Sweden
city: Värnamo
country: Sweden
city: Västervik
country: Sweden
city: Västerås
country: Sweden
city: Örebro
country: Sweden
city: Örnsköldsvik N/A
country: Sweden
city: Östersund
country: Sweden
city: Aarau
country: Switzerland
city: Baden
country: Switzerland
city: Bellinzona
country: Switzerland
city: Chur
country: Switzerland
city: Lausanne
country: Switzerland
city: Nyon
country: Switzerland
city: Schwyz
country: Switzerland
city: Sierre
country: Switzerland
city: Sion
country: Switzerland
city: Wil Sg
country: Switzerland
city: Zurich
country: Switzerland
city: Antrim
country: United Kingdom
city: Basildon
country: United Kingdom
city: Bradford
country: United Kingdom
city: Brighton
country: United Kingdom
city: Cambridge
country: United Kingdom
city: Cardiff
country: United Kingdom
city: Carshalton
country: United Kingdom
city: Derby
country: United Kingdom
city: Doncaster N/A
country: United Kingdom
city: Dundee
country: United Kingdom
city: Edinburgh
country: United Kingdom
city: Exeter
country: United Kingdom
city: Great Yarmouth
country: United Kingdom
city: Inverness
country: United Kingdom
city: Kilmarnock
country: United Kingdom
city: Leicester
country: United Kingdom
city: Londonderry
country: United Kingdom
city: London
country: United Kingdom
city: Manchester
country: United Kingdom
city: Merseyside
country: United Kingdom
city: Merthyr Tydfil
country: United Kingdom
city: Norwich
country: United Kingdom
city: Nottingham
country: United Kingdom
city: Oxford
country: United Kingdom
city: Plymouth
country: United Kingdom
city: Portsmouth
country: United Kingdom
city: Reading
country: United Kingdom
city: Sheffield
country: United Kingdom
city: Shrewsbury
country: United Kingdom
city: Stevenage N/A
country: United Kingdom
city: Suffolk
country: United Kingdom
Study officials:
affiliation: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
name: Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
role: STUDY_DIRECTOR
References: